TWI630387B - METHOD FOR DETECTING A QUATERNARY AMMONIUM COMPOUND HAVING A γ-ACID GROUP, DIAGNOSIS OF CARNITINE DEFICIENCY AND KIT FOR DETECTING THE QUATERNARY AMMONIUM COMPOUND HAVING THE γ-ACID GROUP - Google Patents
METHOD FOR DETECTING A QUATERNARY AMMONIUM COMPOUND HAVING A γ-ACID GROUP, DIAGNOSIS OF CARNITINE DEFICIENCY AND KIT FOR DETECTING THE QUATERNARY AMMONIUM COMPOUND HAVING THE γ-ACID GROUP Download PDFInfo
- Publication number
- TWI630387B TWI630387B TW106103831A TW106103831A TWI630387B TW I630387 B TWI630387 B TW I630387B TW 106103831 A TW106103831 A TW 106103831A TW 106103831 A TW106103831 A TW 106103831A TW I630387 B TWI630387 B TW I630387B
- Authority
- TW
- Taiwan
- Prior art keywords
- acid group
- carboxylic acid
- quaternary ammonium
- solution
- carnitine
- Prior art date
Links
Landscapes
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
Abstract
本發明提供一種具γ-羧酸基之四級銨化合物的檢測方法,可以使一具γ-羧酸基之四級銨化合物帶有螢光團者;一種肉鹼缺乏症的診斷方法,利用前述之具γ-羧酸基之四級銨化合物的檢測方法來檢測取自一疑似患者之樣品中的肉鹼含量,以評估該疑似患者是否罹患肉鹼缺乏症者;及一種用以檢測具γ-羧酸基之四級銨化合物的套組,可以檢測一待測樣品中之具γ-羧酸基之四級銨化合物濃度者。 The present invention provides a method for detecting a quaternary ammonium compound having a γ-carboxylic acid group, which can provide a γ-carboxylic acid quaternary ammonium compound with a fluorophore; a method for diagnosing carnitine deficiency, utilizing The aforementioned method for detecting a quaternary ammonium compound having a γ-carboxylic acid group for detecting a carnitine content in a sample taken from a suspected patient to evaluate whether the suspected patient is suffering from carnitine deficiency; and a method for detecting A kit of quaternary ammonium compounds of a γ-carboxylic acid group capable of detecting a concentration of a quaternary ammonium compound having a γ-carboxylic acid group in a sample to be tested.
Description
本發明係關於一種檢測方法、利用該檢測方法之診斷方法及套組,特別關於一種具γ-羧酸基之四級銨化合物的檢測方法、一種肉鹼缺乏症的診斷方法及一種用以檢測具γ-羧酸基之四級銨化合物的套組。 The present invention relates to a detection method, a diagnostic method and a kit using the same, and particularly to a method for detecting a quaternary ammonium compound having a γ-carboxylic acid group, a method for diagnosing carnitine deficiency, and a method for detecting A kit of quaternary ammonium compounds having a gamma-carboxylic acid group.
具γ-羧酸基之四級銨化合物(如,L-肉鹼、醯基肉鹼、乙醯肉鹼等)為對於人體而言係屬相當重要之分子,惟,此類化合物不僅分子量小,更由於其分子結構中同時具有羧酸基及四級銨基團,因此使該化合物具有高極性而難以萃取,且該具γ-羧酸基之四級銨化合物缺乏螢光團(fluorophore)等發光基團,因而使該具γ-羧酸基之四級銨化合物不適用於習知檢測方法。 A quaternary ammonium compound having a γ-carboxylic acid group (for example, L-carnitine, decylcarnitine, acetaminophen, etc.) is a molecule which is important for the human body, but such a compound has a small molecular weight. Further, since the molecular structure has both a carboxylic acid group and a quaternary ammonium group, the compound has high polarity and is difficult to extract, and the quaternary ammonium compound having a γ-carboxylic acid group lacks a fluorophore. The luminescent group thus makes the quaternary ammonium compound having a γ-carboxylic acid group unsuitable for use in conventional detection methods.
為解決上述問題,本發明提供一種具γ-羧酸基之四級銨化合物的檢測方法,係可以使一具γ-羧酸基之四級銨化合物帶有螢光團,而適用以螢光檢測法進行檢測者。 In order to solve the above problems, the present invention provides a method for detecting a quaternary ammonium compound having a γ-carboxylic acid group, which can have a γ-carboxylic acid group quaternary ammonium compound with a fluorophore, and is suitable for fluorescence. The test method is performed by the tester.
本發明另提供一種肉鹼缺乏症的診斷方法,係利用前述之具γ-羧酸基之四級銨化合物的檢測方法來檢測取自一疑似患者體內之樣品的 肉鹼類含量,以評估該疑似患者是否罹患肉鹼缺乏症者。 The present invention further provides a method for diagnosing carnitine deficiency by detecting a sample taken from a suspected patient by using the aforementioned detection method of a quaternary ammonium compound having a γ-carboxylic acid group. Carnitine content to assess whether the suspected patient is suffering from carnitine deficiency.
本發明更提供一種用以檢測具γ-羧酸基之四級銨化合物的套組,係可以檢測一待測樣品中是否包含具γ-羧酸基之四級銨化合物者。 The present invention further provides a kit for detecting a quaternary ammonium compound having a γ-carboxylic acid group, which is capable of detecting whether a quaternary ammonium compound having a γ-carboxylic acid group is contained in a sample to be tested.
本發明之具γ-羧酸基之四級銨化合物的檢測方法,係包含:提供一樣品,該樣品包含具γ-羧酸基之四級銨化合物;混合該樣品、具有一螢光團之一螢光化合物及一極性非質子溶劑,以形成一反應溶液;將該反應溶液置於80~120℃下1~15分鐘,使該螢光化合物之螢光團與該具γ-羧酸基之四級銨化合物的羧酸基進行一SN2親核取代反應,以獲得一衍生溶液,該衍生溶液包含一衍生物,該衍生物為羧酸基上置換有該螢光化合物之螢光團的具γ-羧酸基之四級銨化合物;於該衍生溶液中加入一萃取劑及一共溶劑,該萃取劑的極性較乙腈的極性高,使該萃取劑及該共溶劑共同形成一油包水之乳劑並分散於該衍生溶液中,以利用該萃取劑萃取該衍生溶液中的衍生物並獲得一待測溶液;及偵測該待測溶液中的衍生物,其中,該具有螢光團之螢光化合物為4-溴甲基聯苯,該極性非質子溶劑為乙腈,該萃取劑為一醋酸銨水溶液,該共溶劑為甲苯;如此藉由該螢光化合物(4-溴甲基聯苯)及該極性非質子溶劑(乙腈)之添加,可以使該具γ-羧酸基之四級銨化合物與該螢光化合物(4-溴甲基聯苯)進行該SN2親核取代反應,而使該具γ-羧酸基之四級銨化合物帶有該螢光團,不僅可以使該具γ-羧酸基之四級銨化合物適用於螢光檢測法,同時可以降低該具γ-羧酸基之四級銨化合物之極性,以利於後續之分離及分析。 The method for detecting a quaternary ammonium compound having a γ-carboxylic acid group of the present invention comprises: providing a sample comprising a quaternary ammonium compound having a γ-carboxylic acid group; mixing the sample and having a fluorescent group a fluorescent compound and a polar aprotic solvent to form a reaction solution; the reaction solution is placed at 80 to 120 ° C for 1 to 15 minutes to make the fluorescent compound of the fluorescent compound and the γ-carboxylic acid group The carboxylic acid group of the quaternary ammonium compound is subjected to an S N 2 nucleophilic substitution reaction to obtain a derivatized solution comprising a derivative which is a fluorophore having a fluorescent compound substituted with the fluorescent compound a quaternary ammonium compound having a γ-carboxylic acid group; adding an extracting agent and a cosolvent to the derivatizing solution, the polarity of the extracting agent is higher than the polarity of the acetonitrile, so that the extracting agent and the cosolvent form an oil together a water-in-water emulsion dispersed in the derivatization solution to extract a derivative in the derivatization solution and obtain a solution to be tested; and detecting a derivative in the solution to be tested, wherein the fluorescent substance is fluorescent The fluorescent compound of the group is 4-bromomethylbiphenyl. The polar aprotic solvent is acetonitrile, the extracting agent is an aqueous solution of ammonium acetate, and the cosolvent is toluene; thus, by adding the fluorescent compound (4-bromomethylbiphenyl) and the polar aprotic solvent (acetonitrile), The quaternary ammonium compound having a γ-carboxylic acid group and the fluorescent compound (4-bromomethylbiphenyl) may be subjected to the S N 2 nucleophilic substitution reaction, and the γ-carboxylic acid group may be subjected to four stages. The ammonium compound carries the fluorophore, and the quaternary ammonium compound having a γ-carboxylic acid group can be applied not only to the fluorescence detection method but also to reducing the polarity of the quaternary ammonium compound having a γ-carboxylic acid group. Conducive to the subsequent separation and analysis.
本發明之具γ-羧酸基之四級銨化合物的檢測方法,其中,該檢測方法另包含:於該反應溶液中加入一鹼劑,續使溶解有該鹼劑之反應溶液進行該SN2親核取代反應,以獲得該衍生溶液;如此可以達成縮短該SN2親核取代反應所需時間。 The method for detecting a quaternary ammonium compound having a γ-carboxylic acid group according to the present invention, wherein the detection method further comprises: adding an alkali agent to the reaction solution, and continuing to cause the reaction solution in which the alkali agent is dissolved to perform the S N 2 nucleophilic substitution reaction to obtain the derivatization solution; thus, the time required to shorten the S N 2 nucleophilic substitution reaction can be achieved.
本發明之具γ-羧酸基之四級銨化合物的檢測方法,其中,檢 測方法另包含:選擇氫氧化鉀、碳酸鉀或碳酸氫鉀作為該鹼劑;如此可以對該SN2親核取代反應提供合適的反應環境。 The method for detecting a quaternary ammonium compound having a γ-carboxylic acid group according to the present invention, wherein the detecting method further comprises: selecting potassium hydroxide, potassium carbonate or potassium hydrogencarbonate as the alkali agent; thus nucleophilic the S N 2 The substitution reaction provides a suitable reaction environment.
本發明之具γ-羧酸基之四級銨化合物的檢測方法,其中,係以逆相層析法、螢光光譜法或質譜分析法偵測該待測溶液中的具γ-羧酸基之四級銨化合物的衍生物;如此可以使該具γ-羧酸基之四級胺化合物容易偵測。 The method for detecting a quaternary ammonium compound having a γ-carboxylic acid group according to the present invention, wherein the γ-carboxylic acid group in the solution to be tested is detected by reverse phase chromatography, fluorescence spectroscopy or mass spectrometry A derivative of the quaternary ammonium compound; thus, the quaternary amine compound having a γ-carboxylic acid group can be easily detected.
本發明之肉鹼缺乏症的診斷方法,係包含:自一疑似患者取得一樣品;以上述具γ-羧酸基之四級銨化合物的檢測方法,於體外偵測該樣品中的肉鹼類化合物之含量,以獲得一偵測值;及比較該樣品的偵測值與一參考值;其中,該偵測值低於該參考值顯示該疑似患者罹患肉鹼缺乏症;如此利用上述具γ-羧酸基之四級銨化合物的檢測方法偵測由該疑似患者取得之樣品,能夠有效地分析該樣品中的肉鹼類含量,以有效地診斷該疑似患者是否罹患肉鹼缺乏症。 The method for diagnosing carnitine deficiency of the present invention comprises: obtaining a sample from a suspected patient; detecting the carnitine in the sample in vitro by the above-mentioned method for detecting a quaternary ammonium compound having a γ-carboxylic acid group; a content of the compound to obtain a detection value; and comparing the detected value of the sample with a reference value; wherein the detected value is lower than the reference value to indicate that the suspected patient suffers from carnitine deficiency; - Detection method of a carboxylic acid-based quaternary ammonium compound The sample obtained from the suspected patient can effectively analyze the carnitine content in the sample to effectively diagnose whether the suspected patient suffers from carnitine deficiency.
本發明之肉鹼缺乏症的診斷方法,其中,偵測該樣品中的L-肉鹼之含量,以獲得該偵測值,及偵測取自一健康個體之樣品中的L-肉鹼之含量,以獲得該參考值。 The method for diagnosing carnitine deficiency according to the present invention, wherein the content of L-carnitine in the sample is detected to obtain the detected value, and the L-carnitine in the sample taken from a healthy individual is detected. The content is obtained to obtain the reference value.
本發明之肉鹼缺乏症的診斷方法,其中,偵測該樣品中的L-肉鹼之含量及乙醯肉鹼之含量,並計算該樣品中的L-肉鹼含量/乙醯肉鹼含量之比值,以獲得該偵測值,及偵測取自一健康個體之樣品中的L-肉鹼之含量及乙醯肉鹼之含量,並計算該健康個體之樣品中的L-肉鹼含量/乙醯肉鹼含量之比值,以獲得該參考值。 The method for diagnosing carnitine deficiency according to the present invention, wherein the content of L-carnitine and the content of acetylcarnitine in the sample are detected, and the L-carnitine content/acetylcholine content in the sample is calculated. Ratio to obtain the detected value, and detect the content of L-carnitine and the content of acetaminophen in a sample taken from a healthy individual, and calculate the L-carnitine content in the sample of the healthy individual. / ratio of acetaminophen content to obtain the reference value.
本發明之用以檢測具γ-羧酸基之四級銨化合物的套組,係包含:一具有螢光團之螢光化合物,該螢光化合物之螢光團用以與該具γ-羧酸基之四級銨化合物的羧酸基進行一SN2親核取代反應以形成一衍生物;一極性非質子溶劑,用以加速該SN2親核取代反應;一萃取劑,用以萃取 該衍生物,該萃取劑的極性較該極性非質子溶劑的極性高;及一共溶劑,用以與該萃取劑共同形成一油包水之乳劑;其中,該具有螢光團之螢光化合物為4-溴甲基聯苯,該極性非質子溶劑為乙腈,該萃取劑為一醋酸銨水溶液,該共溶劑為甲苯;如此確實能夠使包含具γ-羧酸基之四級銨化合物的樣品進行SN2親核取代反應而生成該衍生物,以進一步利用逆相層析法、螢光光譜法或質譜分析法分析。 The kit for detecting a quaternary ammonium compound having a γ-carboxylic acid group of the present invention comprises: a fluorescent compound having a fluorescent group, and a fluorescent group of the fluorescent compound is used for the γ-carboxy group The carboxylic acid group of the acid-based quaternary ammonium compound undergoes a S N 2 nucleophilic substitution reaction to form a derivative; a polar aprotic solvent for accelerating the S N 2 nucleophilic substitution reaction; and an extracting agent for Extracting the derivative, the extracting agent is more polar than the polar aprotic solvent; and a cosolvent for forming a water-in-oil emulsion together with the extracting agent; wherein the fluorescent compound having a fluorescent group Is 4-bromomethylbiphenyl, the polar aprotic solvent is acetonitrile, the extracting agent is an aqueous solution of ammonium acetate, the cosolvent is toluene; thus, it is indeed capable of making a sample containing a quaternary ammonium compound having a γ-carboxylic acid group The S N 2 nucleophilic substitution reaction is carried out to form the derivative, which is further analyzed by reverse phase chromatography, fluorescence spectroscopy or mass spectrometry.
本發明之用以檢測具γ-羧酸基之四級銨化合物的套組,其中,該套組另包含:一鹼劑,該鹼劑為可溶解於該極性非質子溶劑之鹼性化合物,且用以提供進行該SN2親核取代反應的一鹼性環境;如此可以縮短該SN2親核取代反應所需時間。 The kit for detecting a quaternary ammonium compound having a γ-carboxylic acid group, wherein the kit further comprises: an alkali agent which is a basic compound soluble in the polar aprotic solvent, And used to provide an alkaline environment for carrying out the S N 2 nucleophilic substitution reaction; thus, the time required for the S N 2 nucleophilic substitution reaction can be shortened.
本發明之用以檢測具γ-羧酸基之四級銨化合物的套組,其中,該鹼劑為氫氧化鉀、碳酸鉀或碳酸氫鉀;如此可以對該SN2親核取代反應提供合適的反應環境。 The kit for detecting a quaternary ammonium compound having a γ-carboxylic acid group, wherein the alkali agent is potassium hydroxide, potassium carbonate or potassium hydrogencarbonate; thus, the S N 2 nucleophilic substitution reaction can be provided A suitable reaction environment.
第1a圖:係4-溴甲基聯苯與肉鹼進行SN2親核取代反應之反應式。 Of FIG. 1a: Department of 4-bromomethyl-biphenyl-carnitine for the S N 2 nucleophilic substitution reaction of the reaction formula.
第1b圖:係4-溴甲基聯苯與乙醯肉鹼進行SN2親核取代反應之反應式。 Of FIG. 1b: 4-bromomethyl-biphenyl-based and acetylcarnitine for S N 2 nucleophilic substitution reaction of the reaction formula.
第2圖:係第A11~A16及A21~A26組之峰面積比長條圖。 Figure 2: The peak area ratio bar graph of the A11~A16 and A21~A26 groups.
第3圖:係第B11~B16及B21~B26組之峰面積比長條圖。 Figure 3: Peak area ratio bar graph of groups B11~B16 and B21~B26.
第4圖:係第C10~C13及C20~C23組之峰面積比長條圖。 Figure 4: Peak area ratio bar graph of the C10~C13 and C20~C23 groups.
第5圖:係第C11及C21組於80℃下加熱之峰面積比長條圖。 Figure 5: Peak area ratio bar graph of heating in Groups C11 and C21 at 80 °C.
第6圖:係第C11及C21組於90℃下加熱之峰面積比長條圖。 Figure 6: Peak area ratio bar graph of heating in Groups C11 and C21 at 90 °C.
第7圖:係第C11及C21組於100℃下加熱之峰面積比長條圖。 Figure 7: Peak area ratio bar graph of heating in Groups C11 and C21 at 100 °C.
第8圖:係第E11~E16及E21~E26組之峰面積比長條圖。 Figure 8: Peak area ratio bar graph of the E11~E16 and E21~E26 groups.
第9圖:係第F11~F16及F21~F26組之峰面積比長條圖。 Figure 9: The peak area ratio bar graph of the F11~F16 and F21~F26 groups.
第10圖:係第G10~G14及G20~G24組之峰面積比長條圖。 Figure 10: The peak area ratio bar graph of the G10~G14 and G20~G24 groups.
第11圖:係第H10~H14及H20~H24組之峰面積比長條圖。 Figure 11: Peak area ratio bar graph of the H10~H14 and H20~H24 groups.
為讓本發明之上述及其他目的、特徵及優點能更明顯易懂,下文特舉本發明之較佳實施例,並配合所附圖式,作詳細說明如下:本發明所述之「具γ-羧酸基之四級銨化合物」係指具有碳鏈之四級銨化合物中,於γ碳位具有一羧酸基(carboxylic acid group,即-C(=O)OH)者,例如丁基甜菜鹼(butyrobetaine)、肉鹼(L-carnitine)、醯基肉鹼(acyl-L-carnitine species)、肉鹼酒石酸鹽(carnitine tartrate)、肉鹼延胡索酸鹽(carnitine fumarate)或肉鹼檸檬酸鹽(carnitine citrate)等,其中醯基肉鹼包含但不限於乙醯肉鹼(acetyl-L-carnitine)、丙醯肉鹼(propionyl-L-carnitine)、丁醯肉鹼(butyryl-L-carnitine)、異戊醯肉鹼(isovaleryl-L-carnitine)、己醯肉鹼(hexanoyl-L-carnitine)、辛醯肉鹼(octanoyl-L-carnitine)、癸醯肉鹼(decanoyl-L-carnitine)、月桂醯肉鹼(lauroyl-L-carnitine)、肉豆蔻醯肉鹼(myristoyl-L-carnitine)、棕櫚醯肉鹼(palmitoyl-L-carnitine)及硬脂醯肉鹼(stearoyl-L-carnitine)等,係為本發明所屬技術領域之通常知識者可以理解。 The above and other objects, features and advantages of the present invention will become more <RTIgt; - a quaternary ammonium compound of a carboxylic acid group" means a quaternary ammonium compound having a carbon chain having a carboxylic acid group (i.e., -C(=O)OH) at a γ carbon position, such as a butyl group. Butyrobetaine, L-carnitine, acyl-L-carnitine species, carnitine tartrate, carnitine fumarate or carnitine citrate (Carnitine citrate), etc., wherein mercaptocarnitine includes, but is not limited to, acetyl-L-carnitine, propionyl-L-carnitine, butyryl-L-carnitine , isovaleryl-L-carnitine, hexanoyl-L-carnitine, octanoyl-L-carnitine, decanoyl-L-carnitine, Lauroyl-L-carnitine, myristoyl-L-carnitine, palmitoyl-L-carnitine, and hard Stearoyl-L-carnitine and the like are understood by those of ordinary skill in the art to which the present invention pertains.
本發明之一實施例的用以檢測具γ-羧酸基之四級銨化合物的套組係可以包含一具有螢光團(fluorophore)之螢光化合物(fluorescent compound)及一極性非質子溶劑(polar aprotic solvent),該套組係可以應用於檢測一樣品中是否含有具γ-羧酸基之四級銨化合物。 The kit for detecting a quaternary ammonium compound having a γ-carboxylic acid group according to an embodiment of the present invention may comprise a fluorescent compound having a fluorophore and a polar aprotic solvent ( Polar aprotic solvent), the kit can be used to detect whether a sample contains a quaternary ammonium compound having a γ-carboxylic acid group.
該樣品係可以選擇一藥物樣品、一化妝品樣品、一食品樣品、或來自一哺乳生物之生物樣品。詳言之,以該套組檢測該樣品前,可以根據樣品類型來進行合適之前處理,例如離心或乾燥等,係為本發明所 屬技術領域之通常知識者可以理解。 The sample can be selected from a pharmaceutical sample, a cosmetic sample, a food sample, or a biological sample from a mammalian organism. In detail, before the sample is detected by the kit, appropriate pre-treatment, such as centrifugation or drying, can be performed according to the type of the sample, which is the present invention. It is generally understood by those skilled in the art.
更詳言之,係可以混合該樣品、該螢光化合物及該極性非質子溶劑,以形成一反應溶液,使該螢光化合物之螢光團與該具γ-羧酸基之四級銨化合物的羧酸基進行一SN2親核取代反應(SN2 nucleophilic substitution reaction)以形成一衍生物,該衍生物為羧酸基上置換有該螢光化合物之螢光團的具γ-羧酸基之四級銨化合物(為便於後續說明,係將包含該衍生物之該反應溶液稱為一「衍生溶液」)。如此,即可以將該衍生溶液作為一待測溶液,並偵測該待測溶液中的衍生物,以得知該樣品中是否包含具γ-羧酸基之四級銨化合物。 More specifically, the sample, the fluorescent compound and the polar aprotic solvent may be mixed to form a reaction solution to fluoresce the fluorescent compound with the quaternary ammonium compound having a γ-carboxylic acid group. a carboxylic acid group for S N 2 nucleophilic substitution reaction (S N 2 nucleophilic substitution reaction) to form a derivative, the derivative having a carboxylic acid group substituted with a carboxylic γ- fluorophore of the fluorescent compound The acid-based quaternary ammonium compound (for ease of explanation, the reaction solution containing the derivative is referred to as a "derived solution"). Thus, the derivatized solution can be used as a solution to be tested, and the derivative in the solution to be tested can be detected to know whether or not the quaternary ammonium compound having a γ-carboxylic acid group is contained in the sample.
該螢光化合物包含該螢光團及一離去基(leaving group),該SN2親核取代反應中,該具γ-羧酸基之四級銨化合物之羧酸基會於中性或鹼性環境下進行去質子化反應(deprotonation),攻擊該螢光化合物,使該離去基自該螢光化合物脫離,如此,該具γ-羧酸基之四級銨化合物與該螢光化合物之螢光基團即可以共同形成該衍生物;舉例而言,該螢光化合物可以為4-溴甲基聯苯(4-bromomethylbiphenyl)、4-溴乙基聯苯(4-bromoethylbiphenyl)、4-溴甲基-2’-氰基聯苯(4-bromomethyl-2’-cyanobiphenyl)、(2-聯苯)重氮甲烷((2-biphenyl)diazomethane)、4-胺聯苯(4-aminobiphenyl)、聯苯-4-基-氫氯酸肼(biphenyl-4-yl-hydrazine hydrochloride)、4-苯酚(4-phenylphenol)或4-聯苯三氟甲磺酸(4-biphenyl trifluoromethanesulfonate),惟不應以此為限。以4-溴甲基聯苯作為該螢光化合物,且以肉鹼作為該具γ-羧酸基之四級銨化合物之情形,上述SN2親核取代反應之反應式係如第1a圖所示;或者,以4-溴甲基聯苯作為該螢光化合物,且以乙醯肉鹼作為該具γ-羧酸基之四級銨化合物之情形,上述SN2親核取代反應之反應式係如第1b圖所示。 The fluorescence of the fluorophore and the compound comprises a leaving group (leaving group), the S N 2 nucleophilic substitution reaction, the carboxylic acid groups of the quaternary ammonium compound having the carboxylic acid groups will γ- or neutral Performing a deprotonation reaction in an alkaline environment, attacking the fluorescent compound, and detaching the leaving group from the fluorescent compound, such that the quaternary ammonium compound having a γ-carboxylic acid group and the fluorescent compound The fluorescent group may form the derivative together; for example, the fluorescent compound may be 4-bromomethylbiphenyl, 4-bromoethylbiphenyl, 4 -4-bromomethyl-2'-cyanobiphenyl, (2-biphenyl)diazomethane, 4-aminobiphenyl , biphenyl-4-yl-hydrazine hydrochloride, 4-phenylphenol or 4-biphenyl trifluoromethanesulfonate, This should not be limited to this. In the case where 4-bromomethylbiphenyl is used as the fluorescent compound and carnitine is used as the quaternary ammonium compound having a γ-carboxylic acid group, the reaction formula of the above S N 2 nucleophilic substitution reaction is as shown in FIG. 1a. Or as shown in the case of 4-bromomethylbiphenyl as the fluorescent compound and acetaminophen as the quaternary ammonium compound having a γ-carboxylic acid group, the above S N 2 nucleophilic substitution reaction The reaction formula is shown in Figure 1b.
該極性非質子溶劑係用以加速該SN2親核取代反應;舉例而 言,該極性非質子溶劑可以為乙腈。 The polar aprotic solvent is used to accelerate the S N 2 nucleophilic substitution reaction; for example, the polar aprotic solvent can be acetonitrile.
值得注意的是,於形成該反應溶液時,工者可以同時混合該樣品、該螢光化合物及該極性非質子溶劑;或者,工者另可以先將該樣品及該螢光化合物分別溶於該極性非質子溶劑之中,以形成一螢光化合物溶液及一樣品溶液,以便於進行溶液濃度及添加量之計算。例如,混合該樣品與該極性非質子溶劑以形成2μM之該樣品溶液,混合該螢光化合物及該極性非質子溶劑以形成2~35mM之該螢光化合物溶液,續以20μl之該樣品溶液混合5μl之該螢光化合物溶液以形成該反應溶液。 It should be noted that, in forming the reaction solution, the worker may simultaneously mix the sample, the fluorescent compound and the polar aprotic solvent; or the worker may separately dissolve the sample and the fluorescent compound separately. Among the polar aprotic solvents, a fluorescent compound solution and a sample solution are formed to facilitate calculation of the solution concentration and the added amount. For example, mixing the sample with the polar aprotic solvent to form 2 μM of the sample solution, mixing the fluorescent compound and the polar aprotic solvent to form 2 to 35 mM of the fluorescent compound solution, and continuing to mix 20 μl of the sample solution. 5 μl of this fluorescent compound solution was formed to form the reaction solution.
此外,該套組可以進一步包含一鹼劑(base),該鹼劑可以促進該具γ-羧酸基之四級銨化合物之羧酸基的去質子化反應,並進一步促進該SN2親核取代反應的進行。該鹼劑可以使用可溶解於該極性非質子溶劑之鹼性化合物,例如氫氧化鉀、碳酸鉀或碳酸氫鉀,較佳可以選擇氫氧化鉀作為該鹼劑;又,該鹼劑能夠以該極性非質子溶劑調製成一飽和鹼劑溶液,則可以提供合適之鹼性,以獲得最佳之反應效率。 Further, the kit may further comprise a base which promotes deprotonation of the carboxylic acid group of the quaternary ammonium compound having a γ-carboxylic acid group and further promotes the S N 2 pro The nuclear substitution reaction proceeds. The alkaline agent may be a basic compound soluble in the polar aprotic solvent, such as potassium hydroxide, potassium carbonate or potassium hydrogencarbonate, preferably potassium hydroxide is selected as the alkali agent; further, the alkali agent can The polar aprotic solvent is prepared as a saturated alkaline agent solution to provide a suitable base for optimum reaction efficiency.
又,工者可以直接共同混合該鹼劑與該樣品、該螢光化合物及該極性非質子溶劑;或者,同上所述,工者亦可以先將該鹼劑溶解於適量之該極性非質子溶劑中以形成一鹼劑溶液,續與該樣品溶液及該螢光化合物溶液混合。例如,混合該樣品與該極性非質子溶劑以形成2μM之該樣品溶液,混合該螢光化合物及該極性非質子溶劑以形成2~35mM之該螢光化合物溶液,混合該鹼劑及該極性非質子溶劑以形成該飽和鹼劑溶液,續混合20μl之該樣品溶液、5μl之該螢光化合物溶液與2μl之該飽和鹼劑溶液以形成該反應溶液。 Moreover, the worker may directly mix the alkali agent with the sample, the fluorescent compound and the polar aprotic solvent; or, as described above, the worker may first dissolve the alkaline agent in an appropriate amount of the polar aprotic solvent. Forming an alkali solution to continue mixing with the sample solution and the fluorescent compound solution. For example, mixing the sample with the polar aprotic solvent to form 2 μM of the sample solution, mixing the fluorescent compound and the polar aprotic solvent to form 2 to 35 mM of the fluorescent compound solution, mixing the alkali agent and the polarity The protic solvent was used to form the saturated alkaline agent solution, and 20 μl of the sample solution, 5 μl of the fluorescent compound solution and 2 μl of the saturated alkaline agent solution were continuously mixed to form the reaction solution.
進行該SN2親核取代反應時,藉由額外提供熱量,可以加速反應之進行。於本實施例中,係將該反應溶液置於80~120℃下1~15分鐘,以獲得該衍生溶液。舉例而言,於80℃下加熱9分鐘,或於90~100 ℃下加熱7分鐘,均可以迅速完成上述SN2親核取代反應。又,工者能夠依據所使用之容器的受熱狀況,調整加熱時間,以避免該極性非質子溶劑蒸發。 When the S N 2 nucleophilic substitution reaction is carried out, the reaction can be accelerated by additionally supplying heat. In the present embodiment, the reaction solution is placed at 80 to 120 ° C for 1 to 15 minutes to obtain the derivatized solution. For example, the above S N 2 nucleophilic substitution reaction can be rapidly completed by heating at 80 ° C for 9 minutes or at 90 to 100 ° C for 7 minutes. Moreover, the worker can adjust the heating time according to the heating condition of the container used to avoid evaporation of the polar aprotic solvent.
經由上述SN2親核取代反應所獲得之衍生溶液係可以作為該待測溶液,該待測溶液係能夠以逆相層析法、螢光光譜法或質譜分析法進行檢測。舉例而言,該逆相層析法係可以藉由例如窄管式液相層析儀(narrow-bore liquid chromatography)或奈米化液相層析儀(nano liquid chromatography)等高壓液相層析系統來進行。詳而言之,以該逆相層析法檢測時,可以適當稀釋該待測溶液,或進行極性之調整,以及加入內標準品,再加入該窄管式逆相層析儀或該奈米化液相層析儀中。於本實施例中,係將該待測溶液加入甲醇,並加入9-氨基吖啶(9-aminoacridine,作為內標準品)續抽取適量注入該窄管式液相層析儀內分析之。並且,為配合該具γ-羧酸基之四級銨化合物之極性,係選用一甲酸水溶液(含0.2%之甲酸)搭配甲醇進行梯度沖提。 The derivative solution obtained by the above S N 2 nucleophilic substitution reaction can be used as the solution to be tested, which can be detected by reverse phase chromatography, fluorescence spectroscopy or mass spectrometry. For example, the reverse phase chromatography can be performed by high pressure liquid chromatography such as narrow-bore liquid chromatography or nano liquid chromatography. The system is going to work. In detail, when the reverse phase chromatography is used, the solution to be tested may be appropriately diluted, or the polarity may be adjusted, and the internal standard may be added, and then the narrow tubular reverse phase chromatograph or the nanometer may be added. In liquid chromatography. In the present embodiment, the solution to be tested is added to methanol, and 9-aminoacridine (as an internal standard) is added, and an appropriate amount is injected into the narrow-tube liquid chromatograph for analysis. Further, in order to match the polarity of the quaternary ammonium compound having a γ-carboxylic acid group, a gradient aqueous solution of an aqueous solution of formic acid (containing 0.2% of formic acid) in combination with methanol was used.
該質譜分析法係可以用一質荷比偵檢器進行,其偵測極限低且靈敏度高;或者,由於該具γ-羧酸基之四級銨化合物已經藉由該SN2親核取代反應而帶有螢光團,故可以利用該螢光光譜法,即以一螢光偵檢器偵測之。利用該螢光光譜法時,該具γ-羧酸基之四級銨化合物之最大激發波長係為255nm,而最大發射波長係為317nm。 The mass spectrometry method can be performed with a mass-to-charge ratio detector with low detection limit and high sensitivity; or, since the quaternary ammonium compound having a γ-carboxylic acid group has been nucleophilic substituted by the S N 2 The reaction has a fluorophore, so the fluorescence spectroscopy can be used, that is, it is detected by a fluorescent detector. When the fluorescence spectrum method is used, the quaternary ammonium compound having a γ-carboxylic acid group has a maximum excitation wavelength of 255 nm and a maximum emission wavelength of 317 nm.
此外,該套組可以進一步包含一萃取劑(extractant),該萃取劑的極性較該極性非質子溶劑的極性高,係可以用以萃取該衍生溶液中的衍生物,且萃取得到的萃取液亦可以作為該待測溶液,並依照需求選擇該逆相層析法、該螢光光譜法或該質譜分析法檢測該待測溶液中的該具γ-羧酸基之四級銨化合物的衍生物。 In addition, the kit may further comprise an extractant having a polarity higher than that of the polar aprotic solvent, which may be used to extract the derivative in the derivatized solution, and the extracted extract is also As the solution to be tested, and selecting the reverse phase chromatography, the fluorescence spectroscopy or the mass spectrometry to detect the derivative of the quaternary ammonium compound having a γ-carboxylic acid group in the solution to be tested. .
該萃取劑係可以選擇一去離子水或一鹽類水溶液,該鹽類水 溶液係可以選擇一醋酸銨水溶液、一氯化銨水溶液、一氯化鈉水溶液或一碳酸氫銨水溶液。該萃取劑為該鹽類水溶液時,可以藉由鹽類解離後之離子特性幫助該衍生物之萃取。該鹽類水溶液之濃度較佳為1M。又,當該樣品為一血漿樣品時,該萃取劑較佳為1M之醋酸銨水溶液。 The extracting agent can select a deionized water or a salt aqueous solution, the salt water The solution may be selected from an aqueous solution of ammonium acetate, an aqueous solution of ammonium monochloride, an aqueous solution of sodium monochloride or an aqueous solution of ammonium hydrogencarbonate. When the extracting agent is an aqueous solution of the salt, the extraction of the derivative can be assisted by the ionic property of the salt after dissociation. The concentration of the aqueous salt solution is preferably 1M. Further, when the sample is a plasma sample, the extractant is preferably a 1 M aqueous solution of ammonium acetate.
又,該套組可以進一步包含一共溶劑(co-solvent),該共溶劑為低密度且和該萃取劑不互溶之有機溶劑,因此於混合該衍生溶液、該萃取劑及該共溶劑後,可以藉由震盪使該衍生溶液、該萃取劑與該共溶劑形成霧化的狀態(cloudy),詳而言之,該萃取劑與該共溶劑會共同形成一油包水之乳劑並以微小液滴(droplet)之形式分散於該衍生溶液中,以增加該萃取劑與該衍生溶液之接觸面積,藉此可提升利用該萃取劑萃取該衍生溶液中的衍生物之萃取效率。舉例而言,該共溶劑可以選擇為甲苯。 Moreover, the kit may further comprise a co-solvent which is an organic solvent having a low density and being immiscible with the extracting agent, so after mixing the derivatizing solution, the extracting agent and the cosolvent, The derivatization solution, the extracting agent and the co-solvent form a cloud state by shaking, in detail, the extracting agent and the co-solvent together form a water-in-oil emulsion and micro droplets A form of a droplet is dispersed in the derivatizing solution to increase a contact area of the extracting agent with the derivatizing solution, whereby extraction efficiency of extracting the derivative in the derivatizing solution by the extracting agent can be improved. For example, the cosolvent can be selected to be toluene.
此外,於萃取後,即可以分離取得該萃取液;舉例而言,可以利用離心使包含該衍生溶液、該萃取劑及該共溶劑之混合溶液分層,使萃取得到的萃取液分布於下層。 Further, after the extraction, the extract may be obtained by separation; for example, a mixed solution containing the derivatized solution, the extractant, and the co-solvent may be layered by centrifugation, and the extracted extract may be distributed in the lower layer.
此外,本實施例中,於混合該衍生溶液(包含作為該極性非質子溶劑之乙腈)、該萃取劑及該共溶劑時,乙腈係可以幫助該萃取劑分散於該衍生溶液中,藉此可以進一步提升萃取效率。 In addition, in the present embodiment, when the derivatization solution (containing acetonitrile as the polar aprotic solvent), the extracting agent and the cosolvent are mixed, the acetonitrile system can help the extracting agent to be dispersed in the derivatizing solution, thereby Further improve the extraction efficiency.
由於該套組能夠使包含具γ-羧酸基之四級銨化合物的樣品進行該SN2親核取代反應而生成該衍生物,使工者可以進一步利用該逆相層析法、該螢光光譜法或該質譜分析法分析,因此,該套組可以應用於一種具γ-羧酸基之四級銨化合物的檢測方法,詳言之,該檢測方法包含提供該樣品;混合該樣品、該螢光化合物及該極性非質子溶劑,以形成該反應溶液;將該反應溶液置於80~120℃下1~15分鐘,使該螢光化合物之螢光團與該具γ-羧酸基之四級銨化合物的羧酸基進行該SN2親核取代反應,以獲得該衍生溶液,該衍生溶液包含該衍生物;及將該衍生溶液作為該待 測溶液,偵測該待測溶液中的衍生物。 Since the kit is capable of subjecting a sample containing a quaternary ammonium compound having a γ-carboxylic acid group to the S N 2 nucleophilic substitution reaction to form the derivative, the worker can further utilize the reverse phase chromatography, the firefly. Optical spectrometry or mass spectrometry analysis, therefore, the kit can be applied to a method for detecting a quaternary ammonium compound having a γ-carboxylic acid group. In detail, the detection method comprises providing the sample; mixing the sample, The fluorescent compound and the polar aprotic solvent are formed to form the reaction solution; the reaction solution is placed at 80 to 120 ° C for 1 to 15 minutes to make the fluorescent group of the fluorescent compound and the γ-carboxylic acid group The carboxylic acid group of the quaternary ammonium compound is subjected to the S N 2 nucleophilic substitution reaction to obtain the derivatized solution, the derivatized solution comprising the derivative; and the derivatized solution is used as the test solution to detect the solution to be tested Derivatives in.
此外,本發明之一實施例的具γ-羧酸基之四級銨化合物的檢測方法,係可以於該衍生溶液中加入該萃取劑,以利用該萃取劑萃取該衍生溶液中的衍生物,以獲得該待測溶液。 Furthermore, in the method for detecting a quaternary ammonium compound having a γ-carboxylic acid group according to an embodiment of the present invention, the extracting agent may be added to the derivatizing solution to extract a derivative in the derivatizing solution by using the extracting agent. The solution to be tested is obtained.
值得注意的是,藉由該套組可以用於檢測來自該哺乳生物之生物樣品,該套組及該檢測方法更可以應用於檢測一疑似患者體內的肉鹼類化合物之含量,藉此評估該疑似患者是否罹患肉鹼缺乏症。詳言之,首先自該疑似患者取得一樣品,並由一健康個體取得一健康個體之樣品,該二樣品係可以同為一全血樣品、一血清樣品、一血漿樣品或一尿液樣品,並於體外(in vitro)以上述具γ-羧酸基之四級銨化合物的檢測方法分別偵測該二樣品中的肉鹼類化合物之含量,以獲得一偵測值與一參考值,比較該偵測值與該參考值,若該偵測值低於該參考值,則顯示該疑似患者罹患肉鹼缺乏症。 It is worth noting that the kit can be used to detect biological samples from the mammalian organism, and the kit and the detection method can be further applied to detect the content of carnitine compounds in a suspected patient, thereby evaluating the Suspected patients suffering from carnitine deficiency. In detail, a sample is first obtained from the suspected patient, and a sample of a healthy individual is obtained from a healthy individual, the two samples being the same as a whole blood sample, a serum sample, a plasma sample or a urine sample. And detecting, in vitro , the content of the carnitine compound in the two samples by the above detection method of the quaternary ammonium compound having a γ-carboxylic acid group, to obtain a detection value and a reference value, and comparing The detected value and the reference value, if the detected value is lower than the reference value, indicates that the suspected patient suffers from carnitine deficiency.
舉例而言,Inoue F等人及Peng M等人發表健康成人的血漿中的L-肉鹼含量約為17.51~66.14μM(J Chromatogr B Biomed Sci Appl.1999 Aug 6;731(1):83-8.;J Chromatogr A.2013 Dec 6;1319:97-106.),因此前述偵測值可以為該疑似患者之L-肉鹼含量值,且該參考值即可以為該健康個體之L-肉鹼含量值,而當該偵測值為該疑似患者之血漿樣品中的L-肉鹼含量值,則該參考值則可以為66.14μM;又,Hothi DK等人及Flanagen JL等人發表能夠以血漿樣品中的乙醯肉鹼/L-肉鹼的比值作為健康的指標,當乙醯肉鹼/L-肉鹼的比值高於0.25時即表示該個體罹患肉鹼缺乏症(Nephrol Dial Transplant.2006 Sep;21(9):2637-2641.),因此前述偵測值亦可以為該疑似患者之血漿樣品中的L-肉鹼含量/乙醯肉鹼含量的比值,且該參考值即可以為該健康個體之血漿樣品中的L-肉鹼含量/乙醯肉鹼含量的比值,而當該偵測值為該疑似患者之血漿樣品中的L-肉鹼含量/乙醯肉鹼含 量的比值,則該參考值則可以為0.25。 For example, Inoue F et al. and Peng M et al. published a plasma L-carnitine content of about 17.51 to 66.14 μM in healthy adults (J Chromatogr B Biomed Sci Appl. 1999 Aug 6; 731(1): 83- 8.; J Chromatogr A.2013 Dec 6; 1319:97-106.), so the aforementioned detection value may be the L-carnitine content value of the suspected patient, and the reference value may be the L- of the healthy individual. The carnitine content value, and when the detection value is the L-carnitine content value in the plasma sample of the suspected patient, the reference value may be 66.14 μM; in addition, Hothi DK et al. and Flanagen JL et al. Taking the ratio of acetaminophen/L-carnitine in the plasma sample as a health indicator, when the ratio of acetaminophen/L-carnitine is higher than 0.25, the individual is suffering from carnitine deficiency (Nephrol Dial Transplant). .2006 Sep;21(9):2637-2641.), so the aforementioned detection value may also be the ratio of the L-carnitine content/acetylcholine content in the plasma sample of the suspected patient, and the reference value is The ratio of L-carnitine content to acetylcholine content in the plasma sample of the healthy individual, and when the detection value is the blood of the suspected patient L-carnitine content in pulp samples / acetyl carnitine The ratio of the quantity can be 0.25.
為證實本發明確實可以使該具γ-羧酸基之四級銨化合物之羧酸基接合該螢光化合物的螢光團,且可以萃取該具γ-羧酸基之四級胺化合物,並分析該具γ-羧酸基之四級銨化合物,遂進行下述實驗: To confirm that the present invention can surely bond the carboxylic acid group of the quaternary ammonium compound having a γ-carboxylic acid group to the fluorescent group of the fluorescent compound, and extract the quaternary amine compound having a γ-carboxylic acid group, and The quaternary ammonium compound having a γ-carboxylic acid group was analyzed, and the following experiment was carried out:
(A)螢光化合物濃度對SN2親核取代反應之影響 (A) Effect of Fluorescent Compound Concentration on S N 2 Nucleophilic Substitution Reaction
本實驗係以肉鹼(第A11~A16組)及乙醯肉鹼(第A21~A26組)作為該具γ-羧酸基之四級銨化合物,以4-溴甲基聯苯作為該螢光化合物,以配製該反應溶液。其中,各組別之肉鹼、乙醯肉鹼及4-溴甲基聯苯濃度係如下第1表所示。 In this experiment, carnitine (Groups A11 to A16) and acetaminocarnitine (Groups A21 to A26) were used as the quaternary ammonium compound with γ-carboxylic acid group, and 4-bromomethylbiphenyl was used as the firefly. A light compound to prepare the reaction solution. Among them, the concentrations of carnitine, acetaminophen and 4-bromomethylbiphenyl in each group are shown in Table 1 below.
將上述第A11~A16及A21~A26組進行SN2親核取代反應後,續加入甲苯及去離子水進行萃取,並於萃取得到的水相中加入9-氨基吖啶作為內標準品,以窄管式液相層析儀配合螢光偵檢器進行逆相層析,各組之峰面積相對標準品之峰面積計算所得之峰面積比(peak area ratio),記錄如第2圖所示。 The above A11~A16 and A21~A26 groups were subjected to S N 2 nucleophilic substitution reaction, and then toluene and deionized water were continuously added for extraction, and 9-aminoacridine was added as an internal standard in the extracted aqueous phase. Reverse phase chromatography was performed with a narrow tube liquid chromatograph and a fluorescence detector. The peak area ratio of the peak area of each group relative to the peak area of the standard was recorded as shown in Fig. 2. Show.
由第2圖可知,各組皆能夠進行SN2親核取代反應,並能夠經該逆相層析法及該螢光光譜法偵測之。此外,第A11~A14及第A21~A24組之中,隨著4-溴甲基聯苯濃度上升,反應之效率亦隨之提高。而當4-溴甲基聯苯之濃度達到3mM(第A14、A24組)以上時,則無法再提升反應之效率。因此,本實施例的該反應溶液中較佳係包含3mM之該螢光化合物。 As can be seen from Fig. 2, each group was able to carry out the S N 2 nucleophilic substitution reaction and was able to detect it by the reverse phase chromatography and the fluorescence spectrometry. In addition, in the groups A11 to A14 and A21 to A24, as the concentration of 4-bromomethylbiphenyl increases, the efficiency of the reaction also increases. When the concentration of 4-bromomethylbiphenyl reached 3 mM (group A14, group A24), the efficiency of the reaction could not be increased. Therefore, it is preferred that the reaction solution of the present embodiment contains 3 mM of the fluorescent compound.
(B)螢光化合物添加量對SN2親核取代反應之影響 (B) Effect of the amount of fluorescent compound added on the nucleophilic substitution reaction of S N 2
本實驗同樣以肉鹼(第B11~B16組)及乙醯肉鹼(B21~B26組)作為該具γ-羧酸基之四級銨化合物,並預先以2μM之濃度溶解於乙腈中,分別配製為含肉鹼、乙醯肉鹼之乙腈溶液。另取4-溴甲基聯苯作為該螢光化合物,以15mM之濃度溶於乙腈中,配製含4-溴甲基聯苯之乙腈溶液。以如下第2表所示之含肉鹼、乙醯肉鹼之乙腈溶液及含4-溴甲基聯苯之乙腈溶液添加量,分別配製第B11~B16組及第B21~B26組之該反應溶液。 In this experiment, carnitine (groups B11 to B16) and acetaminocarnitine (groups B21 to B26) were used as the quaternary ammonium compound with γ-carboxylic acid group, and dissolved in acetonitrile at a concentration of 2 μM in advance. Formulated as an acetonitrile solution containing carnitine and acetaminophen. Further, 4-bromomethylbiphenyl was used as the fluorescent compound, and dissolved in acetonitrile at a concentration of 15 mM to prepare a solution of 4-bromomethylbiphenyl in acetonitrile. The reaction of the B11~B16 group and the B21~B26 group was prepared by adding the amount of carnitine, acetaminophen acetonitrile solution and 4-bromomethylbiphenyl acetonitrile solution as shown in the second table below. Solution.
將上述第B11~B16及B21~B26組進行SN2親核取代反應後,續加入甲苯及去離子水進行萃取,並於萃取得到的水相中加入9-氨基吖啶作為內標準品,以窄管式液相層析儀配合螢光偵檢器進行逆相層析,各組之峰面積相對標準品之峰面積計算所得之峰面積比,記錄如第3圖所示。 After the above-mentioned B11~B16 and B21~B26 groups were subjected to the S N 2 nucleophilic substitution reaction, the toluene and deionized water were continuously added for extraction, and 9-aminoacridine was added as an internal standard in the extracted aqueous phase. Reverse phase chromatography was carried out with a narrow tube liquid chromatograph and a fluorescence detector, and the peak area ratio of the peak area of each group relative to the peak area of the standard was recorded as shown in Fig. 3.
由第3圖可知,各組皆能夠進行SN2親核取代反應,並能夠經該逆相層析法及該螢光光譜法偵測之。其中,又以加入5μl上述含4-溴甲基聯苯之乙腈溶液(第B12及B22組),可以提供最佳之反應效率。推測係由於5μl上述含4-溴甲基聯苯之乙腈溶液即已提供足量之反應試劑,而隨含4-溴甲基聯苯之乙腈溶液體積增加,整體反應系統之體積亦增大,而導致碰撞效率降低,使反應之效率下降。 As can be seen from Fig. 3, each group was able to carry out the S N 2 nucleophilic substitution reaction and was able to detect it by the reverse phase chromatography and the fluorescence spectrometry. Among them, 5 μl of the above 4-bromomethylbiphenyl-containing acetonitrile solution (Groups B12 and B22) was added to provide optimum reaction efficiency. It is speculated that since 5 μl of the above 4-bromomethylbiphenyl-containing acetonitrile solution has provided a sufficient amount of the reaction reagent, the volume of the overall reaction system increases as the volume of the 4-bromomethylbiphenyl-containing acetonitrile solution increases. As a result, the collision efficiency is lowered, and the efficiency of the reaction is lowered.
(C)該鹼劑種類對SN2親核取代反應效率之影響 (C) Effect of the type of alkali agent on the efficiency of nucleophilic substitution reaction of S N 2
取上述(B)實驗所述含肉鹼之乙腈溶液、含乙醯肉鹼之乙腈溶液及含4-溴甲基聯苯之乙腈溶液,另取如下第3表所示之鹼劑配製含各鹼劑之飽和乙腈溶液。取20μl上述含肉鹼之乙腈溶液混合5μl上述含4-溴甲基聯苯之乙腈溶液,另加入2μl含各鹼劑之乙腈溶液作為第C10~C13組;及取20μl上述含乙醯肉鹼之乙腈溶液混合5μl上述含4-溴甲基聯苯之乙腈溶液,加入2μl含各鹼劑之乙腈溶液作為第C20~C23組,各組之鹼劑種類係如下第3表所示。 Taking the carnitine-containing acetonitrile solution, the acetonitrile-containing acetonitrile solution and the 4-bromomethylbiphenyl-containing acetonitrile solution in the above (B) experiment, and further preparing the alkaline agent as shown in the following Table 3 A saturated acetonitrile solution of an alkaline agent. 20 μl of the above carnitine-containing acetonitrile solution is mixed with 5 μl of the above 4-bromomethylbiphenyl-containing acetonitrile solution, and 2 μl of the acetonitrile solution containing each alkali agent is added as the C10-C13 group; and 20 μl of the above-mentioned acetaminophen-containing carnitine is taken. The acetonitrile solution was mixed with 5 μl of the above-mentioned acetonitrile solution containing 4-bromomethylbiphenyl, and 2 μl of an acetonitrile solution containing each alkali agent was added as the C20-C23 group, and the alkali agent type of each group is shown in Table 3 below.
將上述第C10~C13及C20~C23組進行SN2親核取代反應後,續加入甲苯及去離子水進行萃取,並於萃取得到的水相中加入9-氨基吖啶作為內標準品,以窄管式液相層析儀配合螢光偵檢器進行逆相層析,各組之峰面積相對標準品之峰面積計算所得之峰面積比,記錄如第4圖所示。 After the nucleophilic substitution reaction of S N 2 in the above C10~C13 and C20~C23 groups, the toluene and deionized water are continuously added for extraction, and 9-aminoacridine is added as an internal standard in the extracted aqueous phase. Reverse phase chromatography was carried out with a narrow tube liquid chromatograph and a fluorescence detector, and the peak area ratio of the peak area of each group relative to the peak area of the standard was recorded as shown in Fig. 4.
由第4圖可知,各組皆能夠進行SN2親核取代反應,並能夠經該逆相層析法及該螢光光譜法偵測之。其中,又以第C11及C21組之反應效率最佳,顯示加入氫氧化鉀作為該鹼劑,可以提供適當之鹼性環境以輔助SN2親核取代反應之進行,進而提供最佳之反應效率。 As can be seen from Fig. 4, each group was able to carry out the S N 2 nucleophilic substitution reaction and was able to detect it by the reverse phase chromatography and the fluorescence spectrometry. Among them, the reaction efficiency of Groups C11 and C21 is the best, indicating that the addition of potassium hydroxide as the alkali agent can provide an appropriate alkaline environment to assist the nucleophilic substitution reaction of S N 2 to provide the best reaction. effectiveness.
(D)加熱溫度及時間對SN2親核取代反應效率之影響 (D) Effect of heating temperature and time on the efficiency of nucleophilic substitution reaction of S N 2
取上述混合含肉鹼之乙腈溶液、含4-溴甲基聯苯之乙腈溶液及含氫氧化鉀之飽和乙腈溶液之第C11組(以下稱第C11組),及混合含乙醯肉鹼之乙腈溶液、含4-溴甲基聯苯之乙腈溶液及含氫氧化鉀之飽和乙腈溶液之C21組(以下稱第C21組),分別以不同之加熱溫度及時間進行反應後,續加入甲苯及去離子水進行萃取,並於萃取得到的水相中加入9-氨基吖啶作為內標準品,以窄管式液相層析儀配合螢光偵檢器進行逆相層析,各組之峰面積相對標準品之峰面積計算所得之峰面積比,記錄如第5~7圖所示:於80℃下加熱3、5、7、9、11、13分鐘,記錄為第5圖;於90℃下加熱3、5、7、9、11、13分鐘,記錄為第6圖;及於100℃下加熱3、5、7、9、11、13分鐘,記錄為第7圖。 Taking the above-mentioned mixed carnitine-containing acetonitrile solution, 4-bromomethylbiphenyl-containing acetonitrile solution, and potassium hydroxide-containing saturated acetonitrile solution, group C11 (hereinafter referred to as group C11), and mixing acetaminophen-containing The acetonitrile solution, the acetonitrile solution containing 4-bromomethylbiphenyl and the C21 group (hereinafter referred to as the C21 group) containing the saturated acetonitrile solution of potassium hydroxide are respectively reacted at different heating temperatures and times, and then toluene is continuously added. Deionized water was used for extraction, and 9-aminoacridine was added as an internal standard in the extracted aqueous phase, and reverse phase chromatography was performed with a narrow tube liquid chromatograph and a fluorescent detector, and the peaks of each group were obtained. The area ratio of the area calculated from the peak area of the standard is recorded as shown in Figures 5-7: heating at 80 °C for 3, 5, 7, 9, 11, and 13 minutes, recorded as Figure 5; The mixture was heated at ° C for 3, 5, 7, 9, 11, and 13 minutes and recorded as Fig. 6; and heated at 100 ° C for 3, 5, 7, 9, 11, and 13 minutes, and recorded as Fig. 7.
由第5~7圖可知,各組皆能夠進行SN2親核取代反應,並能夠經該逆相層析法及該螢光光譜法偵測之。其中,於80℃下,加熱9分鐘以上即能夠達到最佳反應效率;於90~100℃下加熱7分鐘以上即能夠達到最佳反應效率。 It can be seen from Figures 5 to 7 that each group is capable of performing a S N 2 nucleophilic substitution reaction and is capable of being detected by the reverse phase chromatography and the fluorescence spectrometry. Among them, the optimum reaction efficiency can be achieved by heating at 80 ° C for 9 minutes or more; and the optimum reaction efficiency can be achieved by heating at 90 to 100 ° C for 7 minutes or more.
(E)共溶劑體積對萃取之影響 (E) Effect of cosolvent volume on extraction
取上述第C11、C21組作為該反應溶液,以進行萃取。如上所述,第C11、C21組之體積皆為27μl。第C11組包含帶有甲基聯苯基團之肉鹼,第C21組包含帶有甲基聯苯基團之乙醯肉鹼,以作為羧酸基上置換有該螢光化合物之螢光團的該具γ-羧酸基之四級銨化合物。以甲苯作為該共溶劑,於C11組添加等量去離子水及不同體積之甲苯以作為第E11~E16組;另於第C21組添加等量去離子水及不同體積之甲苯以作為第E21~E26組,各組之去離子水及甲苯添加量係如下第4表所示。 The above C11 and C21 groups were taken as the reaction solution for extraction. As described above, the volume of the C11 and C21 groups was 27 μl. Group C11 comprises carnitine with a methylbiphenyl group, and Group C21 comprises acetaminophen with a methylbiphenyl group as a fluorophore on which a fluorochemical group is substituted with the fluorescent compound. The quaternary ammonium compound having a γ-carboxylic acid group. Toluene was used as the co-solvent. The same amount of deionized water and different volumes of toluene were added to the C11 group as the E11~E16 group. In addition, the same amount of deionized water and different volumes of toluene were added to the C21 group as the E21~ In the E26 group, the amounts of deionized water and toluene added to each group are shown in Table 4 below.
第E11~E16及E21~E26組分別震盪霧化後,續離心並抽取萃取得到的水相,加入9-氨基吖啶作為內標準品,以窄管式液相層析儀配合螢光偵檢器進行逆相層析,各組之峰面積相對標準品之峰面積計算所得之峰面積比,記錄如第8圖所示。 After the E11~E16 and E21~E26 groups were shaken and atomized separately, the aqueous phase was extracted by centrifugation and extracted, and 9-aminoacridine was added as an internal standard. The narrow-tube liquid chromatography was combined with fluorescence detection. The reverse phase chromatography was carried out, and the peak area ratio of the peak area of each group with respect to the peak area of the standard was recorded as shown in Fig. 8.
由第8圖可知,各組皆能夠進行萃取,並能夠經該逆相層析法及該螢光光譜法偵測之。於第E11~E14及E21~E24組中,隨著甲苯體積上升,由於可以使萃取劑良好地分散於萃取系統中,而使萃取效率上升。 惟,當甲苯體積大於85μl後,則不再對萃取效率造成影響,故係以每27μl之該反應溶液混合5μl之水與85μl之甲苯為最佳。 As can be seen from Fig. 8, each group is capable of extraction and can be detected by the reverse phase chromatography and the fluorescence spectrometry. In the groups E11 to E14 and E21 to E24, as the volume of toluene increased, the extraction efficiency was improved because the extractant was well dispersed in the extraction system. However, when the volume of toluene is more than 85 μl, the extraction efficiency is no longer affected, so that it is preferable to mix 5 μl of water and 85 μl of toluene per 27 μl of the reaction solution.
(F)萃取劑添加量對萃取之影響 (F) Effect of the amount of extractant added on the extraction
取上述第C11、C21組作為該反應溶液,以進行萃取。如上所述,第C11、C21組之體積皆為27μl。第C11組包含帶有甲基聯苯基團之肉鹼,第C21組包含帶有甲基聯苯基團之乙醯肉鹼,以作為羧酸基上置換有該螢光化合物之螢光團的該具γ-羧酸基之四級銨化合物。以甲苯作為該共溶劑,且以去離子水作為該萃取劑,於C11組添加等量甲苯及不同體積之去離子水以作為第F11~F16組;另於第C21組添加等量甲苯及不同體積之去離子水以作為第F21~F26組,各組之去離子水及甲苯添加量係如下第5表所示。 The above C11 and C21 groups were taken as the reaction solution for extraction. As described above, the volume of the C11 and C21 groups was 27 μl. Group C11 comprises carnitine with a methylbiphenyl group, and Group C21 comprises acetaminophen with a methylbiphenyl group as a fluorophore on which a fluorochemical group is substituted with the fluorescent compound. The quaternary ammonium compound having a γ-carboxylic acid group. Toluene was used as the co-solvent, and deionized water was used as the extractant. The same amount of toluene and different volumes of deionized water were added to the C11 group as the F11~F16 group; and the same amount of toluene was added to the C21 group. The volume of deionized water was used as the F21 to F26 group, and the deionized water and toluene addition amounts of each group are shown in Table 5 below.
第F11~F16及F21~F26組分別震盪霧化後,續離心並抽取萃取得到的水相,加入9-氨基吖啶作為內標準品,以窄管式液相層析儀配合螢光偵檢器進行逆相層析,各組之峰面積相對標準品之峰面積計算所得 之峰面積比,記錄如第9圖所示。 After the vortexing and atomization of the F11~F16 and F21~F26 groups respectively, the centrifugally extracting and extracting the extracted aqueous phase, adding 9-aminoacridine as the internal standard, and narrow-tube liquid chromatography with fluorescence detection Reverse phase chromatography was performed, and the peak area of each group was calculated relative to the peak area of the standard. The peak area ratio is recorded as shown in Fig. 9.
由第9圖可知,各組皆能夠進行萃取,並能夠經該逆相層析法及該螢光光譜法偵測之。當該萃取劑之添加量在5~15μl時,皆能夠產生霧化現象;惟該萃取劑之添加量越小,能夠產生較高的濃縮效率,而使峰面積比上升。然而,當該萃取劑之添加量小於5μl時,則會導致該水相難以抽取,故最佳係以每27μl之該反應溶液混合5μl之該萃取劑與85μl之該共溶劑。 As can be seen from Fig. 9, each group is capable of extraction and can be detected by the reverse phase chromatography and the fluorescence spectrometry. When the amount of the extracting agent is 5 to 15 μl, atomization can occur; however, the smaller the amount of the extracting agent, the higher the concentration efficiency and the higher the peak area ratio. However, when the amount of the extracting agent added is less than 5 μl, the aqueous phase is difficult to extract, so that 5 μl of the extracting agent and 85 μl of the cosolvent are preferably mixed per 27 μl of the reaction solution.
(G)該鹽類水溶液之種類對萃取之影響 (G) Effect of the type of the salt aqueous solution on the extraction
取上述第C11、C21組作為該反應溶液,以進行萃取。如上所述,第C11、C21組之體積皆為27μl。第C11組包含帶有甲基聯苯基團之肉鹼,第C21組包含帶有甲基聯苯基團之乙醯肉鹼,以作為羧酸基上置換有該螢光化合物之螢光團的該具γ-羧酸基之四級銨化合物。以甲苯作為該共溶劑,且以該鹽類水溶液作為該萃取劑,於C11組添加85μl之甲苯及1M鹽類水溶液5μl以作為第G10~G14組;另於第C21組添加85μl之甲苯及1M鹽類水溶液5μl以作為第G20~G24組,各組之鹽類種類係如下第6表所示。其中,第G10及G20組係以去離子水(無鹽類添加)取代該鹽類水溶液。 The above C11 and C21 groups were taken as the reaction solution for extraction. As described above, the volume of the C11 and C21 groups was 27 μl. Group C11 comprises carnitine with a methylbiphenyl group, and Group C21 comprises acetaminophen with a methylbiphenyl group as a fluorophore on which a fluorochemical group is substituted with the fluorescent compound. The quaternary ammonium compound having a γ-carboxylic acid group. Toluene was used as the co-solvent, and the salt aqueous solution was used as the extractant. In the C11 group, 85 μl of toluene and 1 M salt aqueous solution 5 μl were added as the G10-G14 group; and in the C21 group, 85 μl of toluene and 1 M were added. 5 μl of a salt aqueous solution was used as the G20 to G24 group, and the salt types of each group are shown in Table 6 below. Among them, the G10 and G20 groups were replaced with deionized water (no salt added) to replace the salt aqueous solution.
第G10~G14及G20~G24組分別震盪霧化後,續離心並抽取萃取得到的水相,加入9-氨基吖啶作為內標準品,以窄管式液相層析儀配合螢光偵檢器進行逆相層析,各組之峰面積相對標準品之峰面積計算所得之峰面積比,記錄如第10圖所示。 After the G10~G14 and G20~G24 groups were shaken and atomized separately, the aqueous phase was extracted by centrifugation and extracted, and 9-aminoacridine was added as an internal standard. The narrow-tube liquid chromatography was combined with fluorescence detection. The reverse phase chromatography was carried out, and the peak area ratio of the peak area of each group with respect to the peak area of the standard was recorded as shown in Fig. 10.
由第10圖可知,各組皆能夠進行萃取,並能夠經該逆相層析法及該螢光光譜法偵測之。其中,又以第G10、G20組之去離子水(無鹽類添加)最佳,第G11、G21組之醋酸銨水溶液次之。 As can be seen from Fig. 10, each group is capable of extraction and can be detected by the reverse phase chromatography and the fluorescence spectrometry. Among them, the deionized water (no salt added) of the G10 and G20 groups is the best, and the ammonium acetate aqueous solution of the G11 and G21 groups is the second.
(H)該鹽類水溶液之種類對血漿樣品萃取之影響 (H) Effect of the type of salt aqueous solution on plasma sample extraction
取人類血漿樣品,加入蛋白質沉澱劑去除蛋白質後,溶於乙腈中並分別加入肉鹼(第H10~H14組)、乙醯肉鹼(第H20~H24組)及丁基甜菜鹼(第H30~H34組),以4-溴甲基聯苯作為該螢光化合物進行SN2親和取代反應。取等量經反應後之血漿樣品,分別加入等量之甲苯作為該共溶劑,以及等量、不同種類之1M鹽類水溶液作為該萃取劑,各組之鹽類種類係如下第7表所示。 Take human plasma samples, add protein precipitant to remove protein, dissolve in acetonitrile and add carnitine (H10~H14 group), acetyl carnitine (H20~H24 group) and butyl betaine (H30~) In group H34), an S N 2 affinity substitution reaction was carried out using 4-bromomethylbiphenyl as the fluorescent compound. The same amount of the plasma sample after the reaction was taken, and an equal amount of toluene was added as the co-solvent, and an equal amount of different kinds of 1 M salt aqueous solution was used as the extracting agent, and the salt types of each group were as shown in the seventh table below. .
第H10~H14、H20~H24及H30~H34組分別震盪霧化後,續離心並抽取萃取得到的水相,加入9-氨基吖啶作為內標準品,以窄管式液相層析儀配合螢光偵檢器進行逆相層析,各組之峰面積相對標準品之峰面積計算所得之峰面積比,記錄如第11圖所示。 After the H10~H14, H20~H24 and H30~H34 groups were shaken and atomized respectively, the aqueous phase was extracted by centrifugation and extracted, and 9-aminoacridine was added as an internal standard, and the narrow-tube liquid chromatography was used. The fluorescence detector was subjected to reverse phase chromatography, and the peak area ratio of the peak area of each group relative to the peak area of the standard was recorded as shown in Fig. 11.
由第11圖可知,各組皆能夠進行萃取,並能夠經該逆相層析法及該螢光光譜法偵測之。其中,對於血漿樣品而言,又以第H11、H21、H31組之醋酸銨水溶液最佳,第H12、H22、H32組之氯化銨水溶液次之。 As can be seen from Fig. 11, each group is capable of extraction and can be detected by the reverse phase chromatography and the fluorescence spectrometry. Among them, for the plasma sample, the ammonium acetate aqueous solution of the H11, H21, and H31 groups was the best, and the ammonium chloride aqueous solution of the H12, H22, and H32 groups was next.
(I)以質譜分析法分析人類血漿樣品 (I) Analysis of human plasma samples by mass spectrometry
取1μl血漿樣品,依據上述進行前處理、SN2親和取代反應及萃取,此處係以去離子水作為萃取劑。於萃取後,續進行逆相層析法,並以質譜分析法分析之,記錄如下第8表。 1 μl of the plasma sample was taken, and pretreatment, S N 2 affinity substitution reaction and extraction were carried out according to the above, and deionized water was used as the extractant. After the extraction, reverse phase chromatography was continued, and analyzed by mass spectrometry, and the eighth table below was recorded.
由第8表可知,本實施例的具γ-羧酸基之四級銨化合物的檢測方法確實能夠使用質譜分析法,並同時偵測到人體內多達13種肉鹼類化合物。 As is apparent from the eighth table, the detection method of the quaternary ammonium compound having a γ-carboxylic acid group of the present example can surely use mass spectrometry and simultaneously detect up to 13 carnitine compounds in the human body.
(J)市售錠劑之分析 (J) Analysis of commercial tablets
取包含肉鹼之錠劑粉碎成粉末後,將該粉末溶於乙腈中並經震盪、離心後取上清液,並依據上述進行SN2親核取代反應及萃取後,以層析法偵測,將測得之肉鹼含量記錄於如下第9表。該錠劑係標示其每錠包含1g之肉鹼。 After the carnitine-containing tablet is pulverized into a powder, the powder is dissolved in acetonitrile, and the supernatant is taken after shaking and centrifugation, and subjected to S N 2 nucleophilic substitution reaction and extraction according to the above, and then detected by chromatography. The measured carnitine content was recorded in Table 9 below. The tablet is indicated to contain 1 g of carnitine per ingot.
第9表:包含肉鹼之錠劑分析結果
由第9表可知,本實施例的具γ-羧酸基之四級銨化合物的檢測方法確實能夠檢測錠劑中的肉鹼含量。此外,能夠根據本實施例的具γ-羧酸基之四級銨化合物的檢測方法提供的分析結果,來判斷所分析之藥物樣品是否符合成分標示之規範,例如,美國藥典規範肉鹼錠劑的實際含量必須為標示含量的90.0%~110.0%。 As is apparent from the ninth table, the detection method of the quaternary ammonium compound having a γ-carboxylic acid group of the present example can surely detect the carnitine content in the tablet. Further, according to the analysis results provided by the detection method of the quaternary ammonium compound having a γ-carboxylic acid group of the present embodiment, it is possible to judge whether the analyzed drug sample meets the specification of the ingredient label, for example, the US Pharmacopoeia specification carnitine lozenge The actual content must be between 90.0% and 110.0% of the indicated content.
(K)市售針劑之分析 (K) Analysis of commercially available injections
取包含肉鹼之針劑,將該針劑與乙腈混合並經震盪、離心後取上清液,並依據上述進行SN2親核取代反應及萃取後,以層析法偵測,將測得之肉鹼含量記錄於如下第10表。該針劑係標示其每5毫升包含1g之肉鹼。 Taking a carnitine-containing injection, mixing the injection with acetonitrile, shaking and centrifuging, taking the supernatant, and performing S N 2 nucleophilic substitution reaction and extraction according to the above, and detecting by chromatography, the measured Carnitine content is reported in Table 10 below. The injection is indicated to contain 1 g of carnitine per 5 ml.
由第10表可知,本實施例的具γ-羧酸基之四級銨化合物的檢測方法確實能夠檢測針劑中的肉鹼含量。同樣地,能夠根據本實施例的具γ-羧酸基之四級銨化合物的檢測方法提供的分析結果,來判斷所分析之藥物樣品是否符成分標示之規範。例如,美國藥典規範肉鹼針劑的實際含量必須為標示含量的90.0%~110.0%。 As is apparent from the tenth table, the detection method of the quaternary ammonium compound having a γ-carboxylic acid group of the present example can surely detect the carnitine content in the injection. Similarly, it is possible to judge whether or not the analyzed drug sample conforms to the specification of the component labeling based on the analysis result provided by the detection method of the quaternary ammonium compound having a γ-carboxylic acid group of the present embodiment. For example, the actual content of the US Pharmacopoeia specification for carnitine injections must be between 90.0% and 110.0% of the indicated content.
(L)市售食品及化妝品之分析 (L) Analysis of commercially available foods and cosmetics
取包含肉鹼類之食品(編號A~D)及化妝品(編號E~L),分別經過樣品前處理,並依據上述進行SN2親核取代反應及萃取後,以層析法偵測,將測得之肉鹼類含量記錄於如下第11表。其中,編號A標示其肉鹼類含量為500mg,編號B標示其肉鹼類含量為250mg,編號C標示其肉鹼類含量為20mg。 Take the carnitine-containing foods (No. A~D) and cosmetics (No. E~L), respectively, after sample pretreatment, and carry out S N 2 nucleophilic substitution reaction and extraction according to the above, and then detect by chromatography. The measured carnitine content is recorded in Table 11 below. Among them, the number A indicates that the carnitine content is 500 mg, the number B indicates that the carnitine content is 250 mg, and the number C indicates that the carnitine content is 20 mg.
由第11表可知,本實施例的具γ-羧酸基之四級銨化合物的檢測方法確實能夠檢測食品或化妝品等不同種類樣品中的肉鹼類含量,亦即,本發明具有「適用於類型之待測樣品」功效。 As is apparent from the eleventh table, the detection method of the quaternary ammonium compound having a γ-carboxylic acid group of the present example can surely detect the carnitine content in different kinds of samples such as foods or cosmetics, that is, the present invention has "applicable to Type of sample to be tested" efficacy.
依據上述實驗,可以證實本發明之具γ-羧酸基之四級銨化合物的檢測方法,藉由螢光化合物及極性非質子溶劑之添加,確實可以使該具γ-羧酸基之四級銨化合物與該螢光化合物進行該SN2親核取代反應,而使該具γ-羧酸基之四級銨化合物帶有該螢光團,達成「使該具γ-羧酸基之四級銨化合物適用於螢光光譜法」功效。同時,藉由使該具γ-羧酸基之四級銨化合物接合該螢光化合物之螢光團,可以降低該具γ-羧酸基之四級銨化合物之極性,以利於後續之分離及分析,例如,利用逆相層析法分離該具γ-羧酸基之四級銨化合物時,可以延長其於逆相層析儀之滯留時間,達成「提升分離效果」功效。 According to the above experiment, the detection method of the quaternary ammonium compound having a γ-carboxylic acid group of the present invention can be confirmed, and the addition of the fluorescent compound and the polar aprotic solvent can surely make the γ-carboxylic acid group have four stages. The ammonium compound and the fluorescent compound undergo the nucleophilic substitution reaction of the S N 2 , and the quaternary ammonium compound having a γ-carboxylic acid group is brought to the fluorophore to achieve “the fourth γ-carboxylic acid group Grade ammonium compounds are suitable for use in fluorescence spectroscopy. Meanwhile, by bonding the quaternary ammonium compound having a γ-carboxylic acid group to the fluorophore of the fluorescent compound, the polarity of the quaternary ammonium compound having a γ-carboxylic acid group can be lowered to facilitate subsequent separation and For analysis, for example, when the quaternary ammonium compound having a γ-carboxylic acid group is separated by reverse phase chromatography, the residence time of the reverse phase chromatograph can be prolonged, and the effect of "lifting separation effect" can be achieved.
本發明之具γ-羧酸基之四級銨化合物的檢測方法,另藉由萃取帶有螢光團之該具γ-羧酸基之四級銨化合物,而能夠提升帶有螢光團之該具γ-羧酸基之四級銨化合物的濃度,進而達成「提升該具γ-羧酸基之四級銨化合物之偵測靈敏度」功效。 The method for detecting a quaternary ammonium compound having a γ-carboxylic acid group of the present invention can further enhance the fluorination group by extracting the quaternary ammonium compound having a γ-carboxylic acid group with a fluorescent group. The concentration of the quaternary ammonium compound having a γ-carboxylic acid group further achieves the effect of "increasing the detection sensitivity of the quaternary ammonium compound having a γ-carboxylic acid group".
本發明之肉鹼缺乏症的診斷方法,利用上述具γ-羧酸基之四級銨化合物的檢測方法偵測由疑似患者取得之樣品,能夠有效地分析該樣品中的肉鹼類含量,達成「有效地診斷肉鹼缺乏症」功效。 In the method for diagnosing carnitine deficiency according to the present invention, the above-mentioned sample obtained by a suspected patient can be detected by using the above-mentioned detection method of a quaternary ammonium compound having a γ-carboxylic acid group, and the carnitine content in the sample can be effectively analyzed. "Effective diagnosis of carnitine deficiency".
本發明之用以檢測具γ-羧酸基之四級銨化合物的套組,確實能夠使包含具γ-羧酸基之四級銨化合物的樣品進行SN2親核取代反應而生成衍生物,且可針對該衍生物進一步利用一分析方法,例如逆相層析法、螢光光譜法或質譜分析法進行分析,達成「檢測樣品中是否包含具γ-羧酸 基之四級銨化合物」功效。 The kit for detecting a quaternary ammonium compound having a γ-carboxylic acid group of the present invention can surely perform a S N 2 nucleophilic substitution reaction on a sample containing a quaternary ammonium compound having a γ-carboxylic acid group to form a derivative. Further, the derivative can be further analyzed by an analytical method such as reverse phase chromatography, fluorescence spectroscopy or mass spectrometry to determine whether or not the sample contains a quaternary ammonium compound having a γ-carboxylic acid group. efficacy.
雖然本發明已利用上述較佳實施例揭示,然其並非用以限定本發明,任何熟習此技藝者在不脫離本發明之精神和範圍之內,相對上述實施例進行各種更動與修改仍屬本發明所保護之技術範疇,因此本發明之保護範圍當視後附之申請專利範圍所界定者為準。 While the invention has been described in connection with the preferred embodiments described above, it is not intended to limit the scope of the invention. The technical scope of the invention is protected, and therefore the scope of the invention is defined by the scope of the appended claims.
Claims (10)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/616,734 US10703969B2 (en) | 2016-09-27 | 2017-06-07 | Detection method for quaternary ammonium compound having γ-carboxyl group |
US16/883,494 US11016096B2 (en) | 2016-09-27 | 2020-05-26 | Detection kit for quaternary ammonium compound having γ-carboxyl group |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662400120P | 2016-09-27 | 2016-09-27 | |
US62/400,120 | 2016-09-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201814286A TW201814286A (en) | 2018-04-16 |
TWI630387B true TWI630387B (en) | 2018-07-21 |
Family
ID=62639291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW106103831A TWI630387B (en) | 2016-09-27 | 2017-02-06 | METHOD FOR DETECTING A QUATERNARY AMMONIUM COMPOUND HAVING A γ-ACID GROUP, DIAGNOSIS OF CARNITINE DEFICIENCY AND KIT FOR DETECTING THE QUATERNARY AMMONIUM COMPOUND HAVING THE γ-ACID GROUP |
Country Status (1)
Country | Link |
---|---|
TW (1) | TWI630387B (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201608010A (en) * | 2014-08-27 | 2016-03-01 | 捷恩智股份有限公司 | Liquid crystal compound, liquid crystal composition, polymer and application thereof |
-
2017
- 2017-02-06 TW TW106103831A patent/TWI630387B/en active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201608010A (en) * | 2014-08-27 | 2016-03-01 | 捷恩智股份有限公司 | Liquid crystal compound, liquid crystal composition, polymer and application thereof |
Non-Patent Citations (3)
Title |
---|
Kamimori H et al., Anal Biochem. 1994 May 1;218(2):417-24. |
王聰,中國海洋大學研究生學位論文,發表日期:20110518. |
王聰,中國海洋大學研究生學位論文,發表日期:20110518. Kamimori H et al., Anal Biochem. 1994 May 1;218(2):417-24. * |
Also Published As
Publication number | Publication date |
---|---|
TW201814286A (en) | 2018-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106153596B (en) | Method for rapidly detecting paraquat and/or diquat | |
Dąbrowska et al. | Analytical approaches to determination of carnitine in biological materials, foods and dietary supplements | |
Zhang et al. | Measurement of neurotransmitters from extracellular fluid in brain by in vivo microdialysis and chromatography–mass spectrometry | |
TW201305561A (en) | Analysis of total homocysteine and methylmalonic acid in plasma by LC-MS/MS from a plasma separator device (PSD) | |
AU2013225661B2 (en) | Methods and kits for detection of coenzyme Q10 | |
JP2020106494A (en) | Method for quantifying ethylamine in biological sample | |
CN105092753A (en) | Application of combination amine metabolism marker and kit and detection method thereof | |
Wang et al. | A new approach for turn-on fluorescence sensing of l-DOPA | |
CN107936035A (en) | A kind of cysteine-modifying graphene quantum dot GQCY and preparation method are with preparing the application on dopamine luciferase assay reagent | |
US10865183B2 (en) | Compounds, reagents, and uses thereof | |
KR20120014736A (en) | Method for analyzing aspirin in plasma with liquid chromatography-mass spectrometry | |
Alhazzani et al. | A selective dual quenching sensor (EY/BG@ CDs) for simultaneous monitoring of gentamicin and ketorolac levels in plasma: a highly efficient platform that caters to the needs of therapeutic drug monitoring | |
TWI630387B (en) | METHOD FOR DETECTING A QUATERNARY AMMONIUM COMPOUND HAVING A γ-ACID GROUP, DIAGNOSIS OF CARNITINE DEFICIENCY AND KIT FOR DETECTING THE QUATERNARY AMMONIUM COMPOUND HAVING THE γ-ACID GROUP | |
US11016096B2 (en) | Detection kit for quaternary ammonium compound having γ-carboxyl group | |
Lu et al. | The recognition of aristolochic acid I based on fluorescence quenching of bovine serum albumin-stabilized gold nanoclusters | |
CN108794369B (en) | Aldehyde group-containing chiral amine recognition probe and preparation method and application thereof | |
CN108586391B (en) | Anthraquinone-modified graphene quantum dot AAG, preparation method thereof and application of anthraquinone-modified graphene quantum dot AAG in preparation of lysine fluorescence detection reagent | |
CN114441683A (en) | Method for measuring milk fat | |
CN112285243B (en) | Treatment method for detecting drug residues in animal tissue sample, confirmation detection method and application thereof | |
TWI585067B (en) | Rapid deriving method for carboxylic compound and analysis method for detecting carnitine-like compounds | |
Wang et al. | On-line Identification of chiral ofloxacin in milk with an extraction/ionization device coupled to electrospray mass spectrometry | |
US10067103B2 (en) | Compounds and methods for PEG metabolite and PEG breakdown product assays | |
AU2015328052B2 (en) | Dissolution testing of hydrophobic active pharmaceutical ingredients such as avermectins with or without pyrantel | |
TWI583659B (en) | Asdllme method for extracting quaternary ammonium compound with low molecular weight and high polarity | |
KR20160147480A (en) | Kit for diagnosis gastric cancer using the change of kynurenine metabolic ratio |